Skip to main content

Table 1 Type of DPP-4 inhibitors, cardiovascular outcomes reported and follow-up time periods

From: Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Studies Type of DPP-4 inhibitors Cardiovascular outcomes reported Mean follow-up time period
Gantz2017 [7] Omarigliptin Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular related death, fatal and non-fatal MI, fata and non-fatal stroke, all-cause mortality, hospitalization for heart failure, hospitalization for heart failure or cardiovascular death 96 weeks
Green2015 [8] Sitagliptin Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, all-cause mortality 152 weeks
Park2015 [9] Unspecified DPP-4 inhibitors All-cause mortality 124 weeks
Scirica2013 [10] Saxagliptin Cardiovascular death/non-fatal MI or non-fatal stroke, all-cause mortality, cardiovascular death, MI, stroke, hospitalization for unstable angina, hospitalization for heart failure, hospitalization for coronary revascularization 109 weeks
Shih2016 [11] Unspecified DPP-4 inhibitors All-cause mortality, MACEs, MI, stroke, heart failure 114 weeks
Wang2015 [12] Sitagliptin Cardiovascular death/non-fatal MI or non-fatal stroke, MI, stroke, cardiovascular mortality 52 weeks
White2013 [13] Alogliptin Cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular mortality, non-fatal MI, non-fatal stroke, all-cause mortality 78 weeks
  1. Abbreviations: DDP-4 Dipeptidyl peptidase 4, MI Myocardial infarction, MACEs Major adverse cardiac events
  2. Primary endpoint: including cardiovascular death/non-fatal MI or non-fatal stroke, cardiovascular related death, fatal and non-fatal MI